New clinical data on Krystal Biotech Inc.'s investigational gene therapy for dystrophic epidermolysis bullosa (DEB), KB-103, found five of six wounds treated with the topical candidate closed completely during a phase II trial and, along with wounds investigators treated in phase I, have stayed closed so far.